Aeglea BioTherapeutics, Inc. (AGLE)
|52 Week Range||0.114-1.56|
|1y Target Est||-|
|DCF Unlevered||AGLE DCF ->|
|DCF Levered||AGLE LDCF ->|
|Debt / Equity||41.43%||Neutral|
Upgrades & Downgrades
Latest AGLE news
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates
11 May 2023
Aeglea Biotherapeutics (AGLE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.37 per share a year ago.
10 Top Penny Stocks To Watch Under $1
25 April 2023
Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race
24 April 2023
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.
Penny Stocks to Buy Now? 7 Under $1 To Watch This Week
24 April 2023
Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?
3 Top Penny Stocks Under $1 To Watch Before Next Week
21 April 2023
Penny stocks to buy for under $1 but are they worth the risk? The post 3 Top Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails
13 April 2023
Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade
14 December 2022
Aeglea (AGLE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Penny Stocks To Buy Now That CPI Is Out? 4 To Watch Before Next Week
10 November 2022
Hot penny stocks to watch after October's CPI report. The post Best Penny Stocks To Buy Now That CPI Is Out?
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates
3 November 2022
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >